Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy

被引:32
作者
Pratesi, G [1 ]
Perego, P [1 ]
Zunino, F [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy
关键词
Bcl-2; phosphorylation; drug response;
D O I
10.1016/S0006-2952(00)00538-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bcl-2 blocks or delays apoptosis in many cell systems. The protein exerts its antiapoptotic effect mainly in the membrane of mitochondria. Indeed, emerging evidence supports that the mitochondrion plays an important role in the cell death pathway, integrating different pro- and antiapoptotic stimuli. Since deregulation of the expression of Bcl-2 occurs in a variety of human tumors, modulation of its function is regarded as an exploitable manipulation for pharmacological intervention in antitumor chemotherapy. Phosphorylation of Bcl-2 has been implicated as an important regulatory mechanism of its function and is a common event in response to antimitotic drugs. Recently, a similar post-transcriptional modification was observed in response to DNA-damaging agents in some tumor systems, but this is not a general finding in response to genotoxic drugs. Current investigations indicate that different signaling pathways may be involved in Bcl-2 phosphorylation, likely dependent on the kinases activated by the various stress stimuli. A better understanding of the molecular mechanisms by which Bcl-2 regulates apoptosis could provide insights for a rational design of approaches to enhance the susceptibility to drug-induced cell death. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:381 / 386
页数:6
相关论文
共 56 条
[1]   Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death [J].
Amarante-Mendes, GP ;
Finucane, DM ;
Martin, SJ ;
Cotter, TG ;
Salvesen, GS ;
Green, DR .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (04) :298-306
[2]  
Basu A, 2000, INT J ONCOL, V16, P497
[3]  
Beale PJ, 2000, BRIT J CANCER, V82, P436
[4]  
Biroccio A, 1999, INT J CANCER, V82, P125, DOI 10.1002/(SICI)1097-0215(19990702)82:1<125::AID-IJC21>3.0.CO
[5]  
2-Q
[6]  
Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO
[7]  
2-5
[8]  
Blagosklonny MV, 1997, CANCER RES, V57, P130
[9]  
CHENG EHY, 1997, SCIENCE, V278, P1996
[10]   Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts [J].
De Cesare, M ;
Pratesi, G ;
Giusti, A ;
Polizzi, D ;
Zunino, F .
BRITISH JOURNAL OF CANCER, 1998, 77 (03) :434-439